I am pleased to report that 2011, despite on-going economic challenges, was a successful and important year for our charity.

During the year, we evolved from CHILDREN with LEUKAEMIA UK to CHILDREN with CANCER UK to become the leading national children's charity dedicated to determining the causes, finding cures and providing care for all children with cancer.

Tragically, over 3,300 youngsters are diagnosed with childhood cancer every year in the UK, and the incidence is increasing.

Thanks to the generosity of our much valued supporters, in 2011, we saw a further increase in our fundraising income. It is thanks to such support that we were able to launch our largest grant round to date as well as our first cooperative funding initiative with Great Ormond Street Hospital Children's Charity, both with one clear aim... to help save more young lives.

As we look back on a successful 2011 and maintain our goals in 2012, we also look forward to 2013 and our milestone 25th anniversary. So much has been achieved throughout these years but there is still much to be done.

We thank you for your interest in our work and look forward to our continued partnership to achieve our aims and help even more children with cancer.

Eddie O’Gorman, OBE
Chairman of Trustees

On the following pages, we illustrate how we have performed against the goals we set for 2011.

Funding life-saving research

Early in 2011, we organised a grant round for research aimed at advancing understanding of the causes of childhood leukaemia and other childhood cancers. In December, this culminated in the award of grants totalling almost £1.5 million for 11 new research projects around the UK.

Our Scientific Advisory Panel was boosted during the year by the addition of Professor Geoff Pilkington, an expert in neuro-oncology. During the year, the panel reviewed our research strategy to incorporate our broadened objectives.

In addition, we have launched our first ever joint allocation of grants with Great Ormond Street Hospital Children's Charity, with each charity pledging to contribute £1 million for new research aimed at improving treatment outcomes for children with cancer.

The successful awards will be formally announced in May 2012.

Our new research strategy sets out a number of formal funding streams through which we will direct the majority of funding. These streams include an annual project grant round for research, a new post-doctoral research fellowship scheme and funding for conferences and workshops. These will be implemented during 2012.

During 2011, we took forward plans for our 2012 international scientific conference, Childhood Cancer 2012, in London from 24th to 26th April with speakers and delegates from around the world focussing on the role played by various early life exposures in the development of childhood cancer.

Front Cover

“Alex was diagnosed with leukaemia in May 2010 when he was three years old. By 5pm that same day, he was in a medically induced coma. We were told that our son's chances of survival were less than 5%. If he did survive, the chances of him not being severely disabled were even less.

Our little boy is a miracle story. He is doing amazingly well now and there are no obvious signs of the brain damage, but we have to keep reminding ourselves of the improvements in survival rates for children with leukaemia.” Debbie, Alex’s mum
In 2011, we continued to work with our friends at CLIC Sargent and granted £200,000 to provide financial assistance to the families of children being treated for cancer through Paul’s Fund.

We provided further funding of £60,000 to Shooting Star CHASE (previously CHASE Hospice Care) to support their work with children and young people with cancer.

We also continued our funding of Paul O’Gorman Lifeline, helping to support their essential work for children with cancer hailing from Eastern Europe.

Thanks to the kindness of our supporters and the generosity of Zippos Circus, we were able to invite children with cancer and their families to a unique day at the circus. We look forward to inviting more children and their families to another special performance in 2012.

We will continue to work with our existing partners including CLIC Sargent and Shooting Star CHASE.

We hope to work with more children’s hospices to help provide better care for children and young people with cancer and their families.

See page 38 - 43 for a full list of grants awarded.

In 2011, we continued to work with our friends at CLIC Sargent and granted £200,000 to provide financial assistance to the families of children being treated for cancer through Paul’s Fund.

We provided further funding of £60,000 to Shooting Star CHASE (previously CHASE Hospice Care) to support their work with children and young people with cancer.

We also continued our funding of Paul O’Gorman Lifeline, helping to support their essential work for children with cancer hailing from Eastern Europe.

In 2011, we considered the possible implication of environmental effects on child health.

We briefed MPs, Peers and Councillors on issues relating to children’s health and are hugely grateful to them for taking the time to meet with us throughout the year to discuss such issues.

We have worked with the Health Protection Agency on a communications project to help explain to the public the potential hazards of exposure to environmental effects.

In 2012, we will continue seeking to influence the development of public health policy relating to childhood cancer.

Lord Willis of Knaresborough will kindly host an event in the House of Lords to highlight recent scientific advances in paediatric oncology and to bring together key stakeholders from all areas of concern.

We are pleased to report that in 2011, despite the continued challenging economic climate, we achieved another modest increase in income, taking our total to just over £11.2 million. This increase is a result of growth of our running events, functions and corporate fundraising.

We rely exclusively on voluntary donations and are extremely grateful to everyone who so generously supports our work.

In 2012, we will build further on our existing and successful activities while we continue to explore potential new fundraising opportunities.

In addition, we will continue to streamline and review our expenditure across the charity to ensure that our costs are kept to a minimum.

As we look forward to our 25th anniversary in 2013, we will continue to plan important initiatives with our existing and much valued supporters.

In the year to 31st December 2011, we were able to increase incoming resources from £11,114,520 to £11,233,470.

Since we made a surplus of £1,559,200 (2010: £3,382,244), our net asset position has continued to strengthen from £7,889,182 to £9,448,382. Our strong net asset position, which exceeds the requirements of our reserves policy, gives us the stability to continue the development of our broader remit to fight all childhood cancers.

See pages 20 - 43 for full disclosure of our financial information.
About childhood cancer

In the UK, around 3,300 children are diagnosed with cancer every year.

Main types of childhood cancer: children aged 0 - 14 years
Great Britain 2001 to 2005

Based on data provided by National Registry of Childhood Tumours
www.ccrg.ox.ac.uk/datasets/registrations.htm

Leukaemias 31%
CNS tumours 25%
Lymphomas 10%
Soft tissue sarcomas 7%
Renal tumours 6%
Neuroblastoma 6%
Bone tumours 4%
Germ cell tumours 3%
Retinoblastoma 3%
Hepatic tumours 1%
Other carcinomas and melanomas 3%
Other 1%

Our work

Survival is increasing...

Survival from childhood cancer has increased dramatically over recent decades – today, around three quarters of children diagnosed with cancer now survive.

However, survival rates vary enormously between the different types of childhood cancer, and even those children who survive can be left with life-long problems as a result of their treatment.

... and there is still much to do.

In 2011, our Trustees agreed a new research strategy that sets out three over-riding aims:

1. We want to understand more about why children develop cancer, to find explanations for the increase in risk and to establish whether prevention is a possibility.

2. We want to drive forward the development of novel approaches to diagnosis, identification of markers of likely outcome and improved treatments for childhood cancer, in order to tackle those forms which still elude successful treatment and to minimise the risk of adverse, treatment-related effects.

3. We want to understand more about the long-term risks faced by childhood cancer survivors, of whom there are now more than 30,000 in the UK.

During 2012, we will be calling for grant applications in different areas of childhood cancer research.

Every funding application received will be carefully scrutinised by the members of our expert Scientific Advisory Panel.

All projects passing this first stage of scrutiny will then be sent out to external experts for specialist review.
**Research into causes**

In 2011, we launched our largest ever grant allocation into the causes of childhood cancer.

Despite the growth in survival rates for children with cancer, we still know relatively little as to why children develop cancer in the first place. This is ever more important as increasing numbers are being diagnosed with cancer.

In April 2011, we launched a call for funding applications for research investigating the causes of childhood cancer. After a rigorous process of peer review, our expert grant panel eventually selected 11 of the most promising projects for funding. The total cost of these 11 new projects, which will all get underway during 2012, is £1.5 million.

These new projects are taking place at centres of research excellence around the UK. Some are looking at the full range of childhood cancers, while others focus specifically on one type of childhood cancer, such as leukaemia, Wilms tumour and neuroblastoma.

As well as advancing our understanding of the causes of childhood cancer, these projects may ultimately give an insight into more effective ways of treating children with cancer.

“My son Max was diagnosed with acute myeloid leukaemia (AML) in 1993, when he was four years old. Following treatment, Max was well for about a year and a half but, two years later, we found a lump in his testicle and Max was diagnosed with rhabdomyosarcoma.

“Max’s doctors carried out various tests to see if they could discover why Max had developed this second cancer – the results of these tests helped the doctors to tailor Max’s treatment to give him the best chance of beating cancer once again.

“Max started his second course of treatment in January 1996. Following complications, the doctors told us there was nothing more they could do, and Max passed away on 22nd January 1997, aged just eight.

“Research into the causes of childhood cancer is so important; I hope that Charles Stiller’s project may help prevent other children from being dealt this cruel double blow of a second cancer.”

Gill, Max’s mum

Case study

Charles Stiller, Director of the National Registry of Childhood Tumours (NRCT), was awarded funding to study the occurrence of second cancers in children.

The risk of developing a second cancer is one of the most serious problems for children who have had intensive treatment for cancer.


Stiller will study the occurrence of early second cancers (i.e. within five years of the first) in children in the latter group to establish what factors influence risk.

He explains: “We will study at least 220 children diagnosed with second cancers, comparing them with children who have not been diagnosed with a second cancer.

“We will obtain detailed information from each child’s hospital records about the treatment received for the first cancer and will look for differences between the two groups. We will also look for the presence of genetic syndromes and birth defects as well as differences in ethnicity and socio-economic status.

“This work should help us establish the risk factors for developing a second cancer.”

This important project will help us to understand why some children develop a second cancer soon after treatment for the first. Ultimately, this work may help to prevent some children from developing a second cancer - if certain types of treatment are associated with an increased risk of second cancers, these risks may be reduced by altering the dose or type of chemotherapy or radiotherapy.

The NRCT is the largest specialist childhood cancer registry in the world. It has virtually complete coverage of childhood cancer across the whole of the UK and, as part of the follow-up of survivors of childhood cancer, the NRCT is routinely informed of subsequent cancers diagnosed in survivors.

To find out more about our research and the projects you are helping to fund, visit www.childrenwithcancer.org.uk/research
In September 2011, we launched a joint funding call with Great Ormond Street Hospital Children’s Charity, the first time we have collaborated in this way.

We invited applications for projects aimed at improving treatments for children with cancer, with each charity pledging £1 million.

Survival rates for children with cancer have improved dramatically over recent decades. However, 300 lives are lost to childhood cancer every year in the UK as a significant number of patients are still failed by current treatments. Even those who survive do not usually come through the experience unscathed as the treatments used to save young lives can themselves cause serious health and development problems.

Through our collaboration with Great Ormond Street Hospital Children’s Charity and our joint funding call, we are working to develop research that will rapidly translate to direct benefits for children and young people with cancer, saving more lives and offering an improved balance between efficacy of treatment and anticipated toxicity.

To find out more about our research work, please visit www.childrenwithcancer.org.uk/research

Research into treatment

Developing targeted treatment for children with high risk cancers

In the UK, cancer is still the leading cause of death in children aged one to 14 years.

In 2011, to try to improve survival for children with high-risk cancers, we awarded £198,011 to help fund a new experimental cancer therapeutics programme at Great Ormond Street Hospital, led by Dr Darren Hargrave.

Advancing knowledge of childhood cancers has enabled the development of a new generation of ‘targeted’ therapies. This programme will help to get these new treatments onto the wards as quickly and as safely as possible.

Lucas developed neuroblastoma whilst he was still in the womb. When he was born with a huge, distended stomach, doctors knew immediately that something was very wrong.

Lucas was diagnosed with neuroblastoma within a few days. His treatment was intensive; he had eight blood transfusions, a lumbar puncture and a course of chemotherapy before he was even two weeks old.

Lucas was one of the lucky ones. He is now a strong, healthy little boy. He will have to visit the consultant every twelve weeks until he is five years old, but the doctors are very happy with his progress.

“To see him now, you wouldn’t know that Lucas had been so unwell. Today, he is a very happy child - our little miracle.”

Luke, Lucas’s dad

Case study

Dr Darren Hargrave is a Consultant Paediatric Oncologist at Great Ormond Street Hospital. He is leading the new experimental cancer therapeutics programme at the hospital, working with colleagues to investigate the use of targeted therapies in a variety of childhood tumours.

He is initially focusing on a new therapy for neuroblastoma, a tumour which develops from nerve tissue. Neuroblastoma affects just under 100 children a year in the UK, mostly very young children.

Dr Hargrave explains: “An antibody therapy known as anti-GD2 has been used with some success in the US in patients with advanced neuroblastoma. Anti-GD2 therapy is a form of immunotherapy which targets the tumour cells.

“This treatment is being studied in Europe as part of a large clinical trial, but we wish to extend the availability of this type of therapy for children in the UK.

The first step is to implement a clinical trial at Great Ormond Street Hospital and CHILDREN with CANCER UK’s funding is helping to make this possible”
Postal appeals

Our postal appeals have been a core part of our fundraising since the charity began in 1988.

Not only do our appeals help us to raise vital funds, but they give us the opportunity to update our supporters about our work and how they are making a difference to the lives of children with cancer.

In 2011, despite the challenging economy, over £3.6 million was donated by generous supporters throughout the UK. We are enormously grateful to everyone who so kindly responded to our mailings.

We are extremely fortunate to benefit from the support of many famous friends; those who generously headed our appeals in 2011 include Jasper Carrott, Robert Powell, Brenda Blethyn, Floella Benjamin, and our trustee Linda Robson.

Rose Kelly, pictured below is a six year old leukaemia survivor who helped us raise over £420,000 from our Christmas cash appeal. We included in the mailing a ‘Christmas Star’, drawn by Rose, who was diagnosed with leukaemia when she was just five months old, and asked our supporters to write a message for children with cancer during the festive season. We are extremely grateful to Rose and her family for their support.

We hold two Grand Draw raffles, one during the summer and the other at Christmas, raising c£1.8 million.

2012 and how you can help

Our postal appeals are one of our key fundraising areas and we will continue to grow and develop our appeals for 2012. Together with traditional mailing appeals, we are also developing additional, innovative channels of communication. If you would like to be added to our mailing list, please send your details to contactus@childrenwithcancer.org.uk

Corporate partnerships

This is an increasingly important area for us. In 2011, we continued to develop our partnerships and succeeded in raising over £700,000.

We welcomed over 30 new businesses on board, from local enterprises to national corporations that share our determination to fight childhood cancer and save young lives.

Deloitte

Our partnership with Deloitte has been extended for another year and, from an initial fundraising target of c£300,000, the partnership has raised over £550,000 to December 2011. Deloitte have supported our work not just through fundraising but also through strategic and operational initiatives and we are extremely grateful for their on-going support.

Lombard

In May 2011, we were delighted to be chosen as Lombard’s Charity of the Year for 2011/2012, having been selected thanks to employee’s nomination and vote. They hope to raise a wonderful £150,000 during the partnership. A sincere thank you to all those who voted for us.

In September 2011, Lombard celebrated their 150th anniversary and, as part of their corporate social responsibility (CSR) strategy, they organised their CSR 150 Challenge. Teams of staff organised a range of fundraising events based around the number 150, including 150 rollercoaster rides, a 150 mile bike ride and a 150 balloon release. We also welcomed a team of 16 Lombard runners to the Royal Parks Half Marathon in November who included the race as part of a bigger challenge.

“Lombard is delighted to be working alongside CHILDREN with CANCER UK as its national partner. We look forward to growing the relationship for such a deserved cause.”

Lewis Orchant,
Chairperson of CSR Board, Lombard
Running events

Over the last 10 years, our runners have raised over £20 million in life-saving funds.

In 2011, in the UK and overseas, over 3,500 energetic supporters took part in a huge variety of runs... from 5ks to triathlons and from 10ks to marathons, raising a significant £2.7 million.

The Virgin London Marathon is a flagship event for CHILDREN with CANCER UK. 1,211 runners joined our Mr Men and Little Miss running team in 2011, including paralysed champion motorcyclist Eddie Kidd, who took 51 days to complete the course.

Mr Happy runs Britain

Andy Jackson, also known as Mr Happy, ran 1,100 miles from John O’Groats to Land’s End over 10 weeks, raising over £40,000. He ran the Virgin London Marathon as part of his epic efforts.

“I was diagnosed with chronic myeloid leukaemia when I was 18. A routine eye test revealed haemorrhaging in the back of my eye, caused by a massive build up of white blood cells, a classic sign of leukaemia.

“Joining the rest of the Mr Men and Little Miss team at the Virgin London Marathon really helped to spur me on, and crossing the finish line in Land’s End surrounded by friends and family was a fantastic moment that will live with me forever. I am eternally grateful to everybody that played a part. Without the support of charities like CHILDREN with CANCER UK, I probably wouldn’t be here today.”

We look forward to welcoming even more runners and growing our programme of races across the UK and around the world. By pounding the streets – whether it’s in London, Paris, Beijing, Sydney or New York - you can help save more young lives.

To join our Mr Men and Little Miss running team, visit www.childrenwithcancer.org.uk/run

Challenges

In 2011, 130 people raised over £210,000 by taking part in 11 challenges on bike or by foot all over the world, ranging from climbing Kilimanjaro to trekking the Sahara to cycling across nine countries in nine days.

One of our key events for 2011 was our first Capital to Capital Cycle Ride. In September, 26 people cycled 320km from London to Paris in our bespoke challenge and raised a wonderful £41,000.

“After hearing and seeing what children who have cancer go through so early in life, I am delighted that my small efforts are making a difference.”

Gerald Cole, aged 61

Community fundraising

From coffee mornings to discos, and from abseiling to quiz nights, our fundraisers are remarkable people whose ideas and commitment are making a significant and real difference in the fight against childhood cancer. In 2011, nearly 1,000 supporters gave their time and energy to raise over £400,000 in their local communities.

Children’s fundraising

Our two challenges - Cheeky Monkey’s Marathon Challenge and the Children’s Marathon Challenge - are fun-filled sponsored challenges. In 2011, nearly 50,000 children from 1,095 schools and groups took part in our unique children’s fundraising challenges, raising £320,000.

We are looking forward to welcoming more individuals, groups and schools to take part in our range of fundraising activities. Whatever you choose to do, we’ll help you every step of the way.

To join our team, visit www.childrenwithcancer.org.uk/support-us
Fundraising highlights

Special events

Tarrant’s Quiz Party
Devised and initially run by Jeremy Beadle, since 1997 we have raised over £1.6 million from our Quiz Parties, from 2008 kindly hosted by Chris Tarrant.

In May 2011, we raised over £150,000. More than £36,000 was donated by our generous guests for one Grand Auction item - funding for a holiday in Tuscany for young cancer patients and their families. This generosity will give 18 families their first holiday following a child’s diagnosis and treatment.

CHILDMEN with CANCER Ball 2011
In November 2011, we raised over £435,000. Our huge thanks to Gabby and Kenny Logan, Jeff Banks, George Layton, Gary Wilmot and Bobby Davro whose participation on the night helped to make our Ball such a success.

Our additional celebrity guests included Ben de Lisi, Theo Paphitis, Robert and Babs Powell, John Rocha and Paul and Stacey Young.

Over £94,000 was donated for our Grand Auction prizes, including a box at Wembley Stadium for an England football fixture in 2012. On the evening, the successful bidder generously donated the prize back to our charity, in addition asking us to invite three families whose children have cancer or are in remission to a well-deserved day out in June 2012. Thank you so much for your heart-warming generosity.

To join our team, visit www.childrenwithcancer.org.uk/fundraising

Zippos Circus
In September 2011, children with cancer and their families were given a unique day at Zippos Circus, being welcomed by celebrities from CBBC and EastEnders before enjoying a two hour, sensational circus extravaganza featuring over 20 performers.

2012 and how you can help

There are many opportunities throughout the year to be involved in our special fundraising events. Whether you’d like to buy tickets, donate items for the auction, join our committee or volunteer on the night, we’d love to hear from you.

To join our team, visit www.childrenwithcancer.org.uk/specialevents

Thank you

It is thanks to the many individuals and organisations who so generously give their time, energy and money to CHILDREN with CANCER UK that we are able to continue our life-saving work. No matter what you do or how much you raise to help us, you are making a difference to children with cancer across the UK.

We are humbled by the courage, commitment and generous support of the many families who have shared their personal experiences to help raise awareness of childhood cancer.

Amongst our many supporters during 2011 were Eddie Kidd, Andy Jackson, Rory Curran, Rose and Alison Kelly, Peter Beckett, Derek Brown, Chris Emmott, Ann Ferguson, Caroline Randerson, Sanrio and Zippos Circus.

Unfortunately, we are unable to mention everyone who has supported us over the past year, but to each and every one of our much valued supporters, we send our heartfelt thanks and warmest good wishes.

These include:
• The thousands of runners who joined our Mr Men and Little Miss running team and all our challenge participants who have truly gone the extra mile to raise much-needed funds
• Our enthusiastic cheering teams who have joined us on race days up and down the country and our post London Marathon recovery team that included medics, masseurs, physiotherapists and podiatrists
• Our dedicated special event committees, volunteers and generous guests
• Our loyal and energetic community fundraisers working hard in their local communities
• The thousands of children who have taken part in our children’s challenges and, of course, their teachers and group leaders for organising the events
• All of our corporate and trust supporters, with a special thanks to Deloitte, Lombard, XL Insurance, Rathbones, Nisa Today’s and Ink Jungle
• All those who have worked on our campaigns to highlight the possible dangers of harmful environmental exposure and to promote precautionary measures, including our supporters in the House of Commons and the House of Lords
• Our scientific advisors including the many external reviewers who have helped by assessing funding proposals for us during the year
• Our celebrity friends who continue to support us in so many ways
• The volunteers who provide such valuable help to our team
• Our dedicated staff - their commitment and passion ensures that we continue to drive forward all areas of our work
CHILDREN with CANCER UK (previously known as CHILDREN with LEUKAEMIA) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987.

The Charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees
Trustees of CHILDREN with CANCER UK, who served during the year were:
Eddie O’Gorman OBE (Chairman)
The Earl Cadogan DL
Professor Denis Henshaw (resigned 23rd February 2011)
Sandra Mileham
Linda Robson
Dr Ian Gibson (resigned 23rd September 2011)
Rodney Seddon (resigned 31st May 2011)
Robert Templeman (appointed 12th January 2012)

Chief Executive
Caroline Blakely
Registered Charity Number
298405
Registered Company Number
4960054
Principal office
51 Great Ormond Street, London WC1N 3JQ
Solicitors
Bates Wells Braithwaite
2-6 Cannon Street, London EC4M 6YH
Auditors
Crowe Clark Whitehill LLP, St Bride’s House, 10 Salisbury Square, London EC4Y 8EH
Bankers
National Westminster Bank plc
30 North Audley Street, London W1A 4UQ
Contact details
CHILDREN with CANCER UK
51 Great Ormond Street, London WC1N 3JQ
Tel: 020 7404 0808 Fax: 020 7404 3666
Email: info@childrenwithcancer.org.uk
www.childrenwithcancer.org.uk

Celebrity Friends
Hugo Amaya-Torres (Chairman)
Russ Abbot • John Altman
Ant & Dec • Anthony Andrews
Jane Asher • Colin Baker
Baroness Floella Benjamin
David Berglas • Christopher Biggins
Cilla Black • Brenda Blethyn
Sir Richard Branson • Tim Brooke-Taylor
Faith Brown • June Brown
Frank Bruno • Max Bygraves
Sir Michael Caine • Brian Cant
Jasper Carrott • George Cole
Graham Cole • Joan Collins
Phil Collins • Jess Conrad
John Conteh • Ronnie Corbett
Bernard Cribbins • Roger Daltrey
Paul Daniels • Jim Davidson
dickie Davies • sharon Davies
Dame Judi Dench • Jason Donovan
Sir Bruce Forsyth • Haruhisa Handa
Ainsley Harriott • Barry Hearn
Bob Hoskins • Jane How
Sir Chris Hoy • Nerys Hughes
Gloria Hunniford • Chris Jarvis
Sir David Jason • Gorden Kaye
Kevin Keegan • Diane Keen
Felicity Kendal • Eddie Kidd
Burt Kwouk • Bonnie Langford
Eddie Large • George Layton
Rosemary Leach • Rula Lenska
Lennox Lewis • Gary Lineker
Joanna Lumley • Linda Lusardi
Sandy Lyle • Sir Paul McCartney
Sir Trevor McDonald • Debbie McGee
Ruth Madoc • Ron Moody
Patrick Mower • Des O’Connor
Tom O’Connor • Bill Oddie
Nick Owen • Nicholas Parsons
Su Pollard • Robert Powell
Pauline Quirke • Sir Steve Redgrave
Annika Rice • Jonathan Ross
Andrew Sachs • Tessa Sanderson
Gerald Scarfe • Phillip Schofield
Pat Sharp • Stacey Solomon
Michaela Strachan • Chris Tarrant
Angela Thorne • Carol Vorderman
Dennis Waterman • Kevin Whately
June Whitfield • Simon Williams
Gary Wilmot • Sir Terry Wogan
Paul Young

Where the money came from
Where the money went

Appeals and associated donations 32%
Running events 24%
Corporate and trust donations 11%
Legacies 3%
Investments and other 2%
Committing giving 10%
Community fundraising 6%
Special events and trading 6%
Research into prevention and causes 26.8%
Welfare 31.2%
Costs of generating funds 15.2%
Governance costs 0.7%
Raising awareness and education 12.4%
Research into treatment 13.7%
Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice (SORP) Accounting and Reporting by Charities (2005).

Governing documents

These accounts are for CHILDREN with CANCER UK and its subsidiary Helping Children with Cancer Limited.

CHILDREN with CANCER UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006 and 12th May 2007. On 14 May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to CHILDREN with CANCER UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The Charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Objects

The objects as amended by written resolution of 12 May 2007 are shown below:

1. To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
2. To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
3. To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the Charity in relation to its charitable purpose as set out by the objects above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a current total of five members (six members in 2010). The Trustees of the Charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

Trustee appointment and induction

There were no new appointments to the Trustee Board in 2011 (2010: none). The selection of Trustees is made based on vacancies arising, sympathy with the objects of the Charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication ‘The Essential Trustee: What you need to know’ as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the Charity.

Management

The Trustees exercise executive responsibility for the governance of the Charity and, through the Chairman, supervise the management of the Charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as appropriate.

It is the Trustees’ policy to work with other relevant charities and during the course of 2011, the Charity worked closely with Leukaemia and Lymphoma Research, Great Ormond Street Hospital Children’s Charity, CLIC Sargent, Venik Trust and Paul O’Gorman Lifeline.

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the Charity’s risk management process the Trustees acknowledge their responsibility for the Charity’s system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity’s objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

The Trustees keep under regular review the major risks that could affect their achievement of the Charity’s objectives. The Charity also periodically engages professional advisers to facilitate the Charity’s risk assessment process.

Our main risk is our susceptibility to changes in the economic and financial environment. Since we rely solely on discretionary donations from the public, adverse economic conditions can impact our ability to maximise fundraising. However, we have contingency plans and a stable reserve position in place to mitigate such risks.
The Charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposit, to meet fluctuating needs. It is felt that this amount of cash should be in line with the level of reserves.

Cash balances generally are increasing over time since more funds are being kept available to meet longer term grant commitments. The Trustees are keen to ensure that these funds are not exposed to any risk since this cash value has already been promised to grant holders.

Grant making policy

It is the Trustees’ policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2011, a total of £1,760,000 was awarded to welfare projects.

Research grants

An increasing proportion of the Charity’s output is achieved through scientific and medical research. Capital funding for scientific institutions is now being decreased as a proportion of the Charity’s total output in favour of revenue funding for research. In 2011, a total of £2,310,360 was awarded to research projects and a further £251,743 on a project to provide education and raise awareness.

The Trustees openly invite research applications and the criteria is displayed on our website as well as advertisements in scientific publications.

Reserves

The Trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the Charity to meet its objectives. The Trustees have reviewed their reserves policy during the course of the year and agreed to continue to aim to find a balance between maximising charitable work and the need for preparation for contingencies. Consideration was given to assessing the risk, probability and likely impact on the Charity’s ability to meet its financial obligations and reduce expenditure following any short-term decline in income.

Since the Charity relies solely on donated income, the Trustees feel it is necessary to hold reserves of between £8m and £10m, to mitigate the risks associated with such income streams and to give the Charity the stability to continue the development of its broader remit to fight childhood cancers. Unrestricted reserves are currently at the higher end of this range at £9.5m.

Investments

The Memorandum of Association allows the Charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The Charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposit, to meet fluctuating needs. It is felt that this amount of cash should be in line with the level of reserves.

Cash balances generally are increasing over time since more funds are being kept available to meet longer term grant commitments. The Trustees are keen to ensure that these funds are not exposed to any risk since this cash value has already been promised to grant holders.

Grant making policy

It is the Trustees’ policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2011, a total of £1,760,000 was awarded to welfare projects.

Research grants

An increasing proportion of the Charity’s output is achieved through scientific and medical research. Capital funding for scientific institutions is now being decreased as a proportion of the Charity’s total output in favour of revenue funding for research. In 2011, a total of £2,310,360 was awarded to research projects and a further £251,743 on a project to provide education and raise awareness.

Project funding in these areas is directed in two ways:

1. Research into treatment

The Charity works in partnership with Leukaemia and Lymphoma Research Fund, Great Ormond Street Hospital Children’s Charity, University College London, Cancer Research UK and other institutions giving grants in support of the parts of their programmes that are relevant to the Charity’s objects.

2. Research into prevention and causes

The Charity advertises for project applications that are then subject to peer review and scrutiny by our panel of scientific advisors before the Trustees determine which projects to support.

It is also the Trustees’ policy to support directly a number of long-term programmes of research at UK institutions in areas which are of wide ranging importance in relation to childhood cancer.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue to operate.

Statement of Trustees’ responsibilities

The Trustees are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and regulations.

Under company law the Trustees must not approve the financial statements unless they are satisfied that the financial statements are a true and fair view of the state of affairs of the charitable company and the group and of its net incoming resources for the period.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the directors of the company at the date of approval of this report is aware there is no relevant audit information (information needed by the company’s auditor in connection with preparing the audit report) of which the company’s auditor is unaware. Each director has taken all of the steps that he/she should have taken as a director in order to make himself/herself aware of any relevant audit information and to establish that the company’s auditor is aware of that information.

Approved by the Board and signed on its behalf on 31st August 2012.

Eddie O’Gorman OBE
Chairman of Trustees

Independent Auditor’s Report to the Trustees of CHILDREN with CANCER UK

We have audited the financial statements of Children with Cancer UK for the year ended 31 December 2011 set out pages 26 to 43. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Statement of Trustees’ Responsibilities, the trustees (who are also the directors of the charitable company for the purpose of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board’s Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company’s circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees’ Annual Report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:
- give a true and fair view of the state of the group’s and the charitable company’s affairs as at 31 December 2011 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Trustees Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- the parent charitable company has not kept adequate accounting records; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees’ remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Pesh Framjee, Senior Statutory Auditor
12th September 2012
For and on behalf of Crowe Clark Whitehill LLP, Statutory Auditor, St Bride’s House, 10 Salisbury Square, London, EC4Y 8EH
## Financial information

**Consolidated statement of financial activities for the year ended 31st December 2011**

*(incorporating an income and expenditure account)*

<table>
<thead>
<tr>
<th>Note</th>
<th>Total funds</th>
<th>Total unrestricted funds</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>restricted</td>
<td>unrestricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Incoming resources

Voluntary Income

- Appeals and associated donations: £927,640
- Committed giving: £1,118,805
- Schools and children’s groups fundraising: £318,562
- Running Events: £2,659,354
- Community fundraising: £685,101
- Corporate and trust donations: £306,850
- Legacies: £647,160

**Total incoming resources:** £1,234,490

### Resources expended

Costs of generating funds

- Costs of generating voluntary income: £35,560
- Costs of special events and trading: £187,955
- Corporate and trust donations: £306,850
- Legacies: £647,160

**Total resources expended:** £1,234,490

### Net incoming resources before transfers

- **Net incoming resources before transfers:** £306,850

### Gross transfers between funds

- **Gross transfers between funds:** £306,850

### Net movement in funds

- **Net movement in funds:** £7,762,276

### Net current assets

- **Net current assets:** £9,448,382

### Total assets less current liabilities

- **Total assets less current liabilities:** £11,996,936

### The notes on pages 29 - 43 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 31st August 2012.

The Earl Cadogan DL  
Trustee

Eddie O’Gorman OBE  
Trustee
## Consolidated cash flow statement for the year ended 31st December 2011

<table>
<thead>
<tr>
<th>Note</th>
<th>2011 £</th>
<th>2010 £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash inflow from operating activities a)</td>
<td>1,702,691</td>
<td>2,625,311</td>
</tr>
<tr>
<td>Investment income</td>
<td>209,280</td>
<td>101,597</td>
</tr>
<tr>
<td>Increase in liquid resources b)</td>
<td>1,911,971</td>
<td>2,726,908</td>
</tr>
</tbody>
</table>

### Notes to the Cash flow Statement

#### a) Reconciliation of changes in resources to net cash inflow from operating activities

<table>
<thead>
<tr>
<th></th>
<th>2011 £</th>
<th>2010 £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net incoming resources</td>
<td>1,559,200</td>
<td>3,382,244</td>
</tr>
<tr>
<td>Investment income</td>
<td>(209,280)</td>
<td>(101,597)</td>
</tr>
<tr>
<td>Decrease/(Increase) in debtors</td>
<td>339,473</td>
<td>(13,795)</td>
</tr>
<tr>
<td>Increase/(Decrease) in creditors</td>
<td>13,298</td>
<td>(641,541)</td>
</tr>
<tr>
<td>Net cash inflow from operating activities</td>
<td>1,702,691</td>
<td>2,625,311</td>
</tr>
</tbody>
</table>

#### b) Analysis of net funds

<table>
<thead>
<tr>
<th></th>
<th>1 January 2011 £</th>
<th>Cashflow £</th>
<th>31 December 2011 £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash at bank and in hand</td>
<td>1,083,151</td>
<td>(78,029)</td>
<td>1,005,122</td>
</tr>
<tr>
<td>Cash held as short term investments</td>
<td>4,150,000</td>
<td>(510,000)</td>
<td>3,640,000</td>
</tr>
<tr>
<td>Cash held as long term investments</td>
<td>7,000,000</td>
<td>2,500,000</td>
<td>9,500,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>12,233,151</strong></td>
<td><strong>1,911,971</strong></td>
<td><strong>14,145,122</strong></td>
</tr>
</tbody>
</table>

## Notes to the financial statements for the year ended 31st December 2011

### 1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

#### (a) Accounting conventions

The financial statements are prepared in accordance with applicable accounting standards, the Companies Act 2006 and the Statement of Recommended Practice (SORP): Accounting and Reporting by Charities, published in March 2005 in all material respects and are prepared under the historical cost convention.

#### (b) Group status and basis of consolidation

CHILDREN with CANCER UK is the ultimate parent company. It has one subsidiary: Helping Children with Cancer Limited.

CHILDREN with CANCER UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. The consolidated financial statements incorporate the results of CHILDREN with CANCER UK and Helping Children with Cancer Limited using the line by line basis.

#### (c) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

#### (d) Incoming resources

Income is recognised in the period in which the Charity is entitled to receipt and the amount can be measured with reasonable certainty. In accordance with this policy, legacies are included when the Charity is advised by the personal representative of an estate that payment will be made or property transferred and the amount involved can be quantified.

Voluntary income in the form of donations, proceeds of appeals and other fundraising activities are recognised upon receipt.
(e) Resources expended and basis of allocation of costs
All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 4 of the financial statements.

Cost of generating funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

Governance costs are the costs incurred to manage the Charity in compliance with constitutional and statutory requirements.

(f) Taxation
CHILDREN with CANCER UK, as a registered charity, is exempt from taxation of income falling within Section 505 of the Taxes Act 1988 or section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that this is applied to its charitable objectives. No tax charge has arisen in the year.

(g) Tangible fixed assets
Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

(h) Pension scheme
Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Bank of Scotland which was established on 14 September 2001. In 2011, the Charity made a contribution of 12% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(i) Going Concern
After making enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue its activities for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements as outlined in the Statement of Trustees’ Responsibilities on pages 23-24.

(j) Investments
All investments are currently held as cash deposits with variable interest rates.

During the year, the charity disposed of fixed interest bonds that were held at a cost of £1m. The difference between the investment cost and proceeds realised a gain of £29,341 that has been included within investment income.

2. Total resources expended

<table>
<thead>
<tr>
<th>Research into Prevention &amp; Causes £</th>
<th>Research into Treatment £</th>
<th>Welfare £</th>
<th>Raising Awareness and Education £</th>
<th>Cost of generating voluntary income £</th>
<th>Cost of special events and trading £</th>
<th>2011 Total £</th>
<th>2010 Total £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff costs</td>
<td>144,216</td>
<td>126,476</td>
<td>185,937</td>
<td>289,253</td>
<td>32,291</td>
<td>283,324</td>
<td>35,906</td>
</tr>
<tr>
<td>Direct charitable spend</td>
<td>2,445,930</td>
<td>1,197,234</td>
<td>2,834,916</td>
<td>909,910</td>
<td>-</td>
<td>-</td>
<td>340,475</td>
</tr>
<tr>
<td>Printing, postage &amp; stationery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>340,475</td>
</tr>
<tr>
<td>Function and venue costs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>610,776</td>
</tr>
<tr>
<td>Other expenditure</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>47,944</td>
</tr>
<tr>
<td>Audit fee</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>27,800</td>
<td>-</td>
<td>-</td>
<td>27,800</td>
</tr>
<tr>
<td>Other office costs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,933</td>
<td>-</td>
<td>-</td>
<td>9,933</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,590,146</strong></td>
<td><strong>1,323,710</strong></td>
<td><strong>3,020,853</strong></td>
<td><strong>1,199,163</strong></td>
<td><strong>69,924</strong></td>
<td><strong>1,282,519</strong></td>
<td><strong>187,955</strong></td>
</tr>
</tbody>
</table>

3. Support costs
Support costs are allocated to the activities as follows:

<table>
<thead>
<tr>
<th>Research into Prevention &amp; Causes £</th>
<th>Research into Treatment £</th>
<th>Welfare £</th>
<th>Raising Awareness and Education £</th>
<th>Costs of generating voluntary income £</th>
<th>2011 Total £</th>
<th>2010 Total £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central services</td>
<td>24,665</td>
<td>21,250</td>
<td>33,564</td>
<td>43,577</td>
<td>2,374</td>
<td>53,878</td>
</tr>
<tr>
<td>Operational management</td>
<td>7,826</td>
<td>7,545</td>
<td>15,968</td>
<td>17,547</td>
<td>36,898</td>
<td>3,509</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>32,511</strong></td>
<td><strong>28,796</strong></td>
<td><strong>49,532</strong></td>
<td><strong>61,124</strong></td>
<td><strong>41,272</strong></td>
<td><strong>57,387</strong></td>
</tr>
</tbody>
</table>

Central office overheads are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the Charity is allocated on a month by month basis throughout the year. Overheads and staff costs are then allocated to the various charitable activities based on this staff time basis.
4. Costs of charitable activities

<table>
<thead>
<tr>
<th>Activities undertaken directly</th>
<th>Grant funding of activities*</th>
<th>Support costs</th>
<th>2011 Total</th>
<th>2010 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research into:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention &amp; Causes</td>
<td>924,328</td>
<td>1,633,307</td>
<td>32,511</td>
<td>1,813,232</td>
</tr>
<tr>
<td>Research into Treatment</td>
<td>1,096,904</td>
<td>198,011</td>
<td>28,795</td>
<td>1,035,005</td>
</tr>
<tr>
<td>Welfare</td>
<td>1,211,321</td>
<td>1,760,000</td>
<td>49,532</td>
<td>2,877,352</td>
</tr>
<tr>
<td>Raising Awareness &amp; Education</td>
<td>886,296</td>
<td>251,743</td>
<td>61,124</td>
<td>648,632</td>
</tr>
<tr>
<td>Total</td>
<td>4,118,849</td>
<td>3,843,061</td>
<td>171,962</td>
<td>6,374,221</td>
</tr>
</tbody>
</table>

* includes £479,042 of grants reversed from previous years (notes 9 and 15)

5. Results of the parent charity

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total incoming resources</td>
<td>11,221,012</td>
<td>11,126,799</td>
</tr>
<tr>
<td>Total resources expended</td>
<td>(9,661,812)</td>
<td>(7,744,555)</td>
</tr>
<tr>
<td>Net movement in funds</td>
<td>1,559,200</td>
<td>3,382,244</td>
</tr>
</tbody>
</table>

6. Investments

During 2011, the Charity reclassified part of the current assets investment balance as fixed asset investments. £9,500,000 (2010: £7,000,000) has been reclassified because it was felt that this better reflected the purpose of holding this cash.

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market value of investments at 1 Jan</td>
<td>7,000,000</td>
<td>6,300,000</td>
</tr>
<tr>
<td>Additions</td>
<td>3,470,659</td>
<td>704,000</td>
</tr>
<tr>
<td>Disposals</td>
<td>(1,000,000)</td>
<td>-</td>
</tr>
<tr>
<td>Realized Gain</td>
<td>29,341</td>
<td>-</td>
</tr>
<tr>
<td>Unrealised Loss</td>
<td>-</td>
<td>(4,000)</td>
</tr>
<tr>
<td>Market value of investments at 31 Dec</td>
<td>9,500,000</td>
<td>7,000,000</td>
</tr>
</tbody>
</table>

Investments comprise the following:

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash Deposit Funds</td>
<td>9,500,000</td>
<td>6,000,000</td>
</tr>
<tr>
<td>Fixed Interest Bonds</td>
<td>-</td>
<td>130,000</td>
</tr>
<tr>
<td>Cash for Reinvestment</td>
<td>-</td>
<td>870,000</td>
</tr>
<tr>
<td>Total investments at 31 Dec</td>
<td>9,500,000</td>
<td>7,000,000</td>
</tr>
</tbody>
</table>

Investment in subsidiary

CHILDREN with CANCER UK holds 100% of the share capital of Helping Children with Cancer Limited. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship. Any taxable profits made by Helping Children with Cancer UK are donated to CHILDREN with CANCER UK under Gift Aid.

The income and expenditure for the year ended 31 December 2011 is as follows:

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income</td>
<td>29,245</td>
<td>34,912</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(8,353)</td>
<td>(9,857)</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>(12,861)</td>
<td>(16,900)</td>
</tr>
<tr>
<td>Profit on ordinary activities before gift aid and taxation</td>
<td>8,031</td>
<td>8,155</td>
</tr>
</tbody>
</table>

The balance sheet for the subsidiary as at 31 December 2011 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets</td>
<td>39,745</td>
<td>45,877</td>
</tr>
<tr>
<td>Liabilities</td>
<td>(39,645)</td>
<td>(45,777)</td>
</tr>
<tr>
<td>Reserves</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
7. Trustees’ emoluments

The Trustees received no remuneration or reimbursement of expenses during the year (2010 Nil).

8. Debtors

<table>
<thead>
<tr>
<th></th>
<th>2011 Group</th>
<th>2011 Charity</th>
<th>2010 Group</th>
<th>2010 Charity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade debtors</td>
<td>61,426</td>
<td>57,505</td>
<td>25,399</td>
<td>20,740</td>
</tr>
<tr>
<td>Amounts due from subsidiary undertakings</td>
<td>-</td>
<td>35,394</td>
<td>-</td>
<td>41,462</td>
</tr>
<tr>
<td>Other debtors</td>
<td>104,579</td>
<td>104,579</td>
<td>411,059</td>
<td>411,654</td>
</tr>
<tr>
<td>Accrued income</td>
<td>109,302</td>
<td>95,166</td>
<td>154,760</td>
<td>136,859</td>
</tr>
<tr>
<td>Prepayments</td>
<td>1,111,316</td>
<td>1,111,316</td>
<td>1,134,908</td>
<td>1,134,908</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1,386,623</td>
<td>1,403,960</td>
</tr>
</tbody>
</table>

9. Grants to third parties

<table>
<thead>
<tr>
<th></th>
<th>2011 £</th>
<th>2010 £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding liabilities at the start of the year</td>
<td>5,776,775</td>
<td>6,347,954</td>
</tr>
<tr>
<td>Awarded during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research into prevention and causes</td>
<td>2,112,349</td>
<td>702,818</td>
</tr>
<tr>
<td>Research into treatment</td>
<td>198,011</td>
<td>120,000</td>
</tr>
<tr>
<td>Welfare</td>
<td>1,760,000</td>
<td>1,173,733</td>
</tr>
<tr>
<td>Raising Awareness &amp; Education</td>
<td>251,743</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>4,322,103</td>
<td>1,996,551</td>
</tr>
<tr>
<td>Under-spends on previous grant awards</td>
<td>(479,042)</td>
<td>(57,031)</td>
</tr>
<tr>
<td>Paid during the year</td>
<td>(3,775,925)</td>
<td>(2,564,381)</td>
</tr>
<tr>
<td>Foreign exchange loss</td>
<td>21,501</td>
<td>43,682</td>
</tr>
<tr>
<td>Outstanding liabilities at the end of the year</td>
<td>5,865,412</td>
<td>5,776,775</td>
</tr>
<tr>
<td>Grants falling due within one year</td>
<td>3,316,858</td>
<td>3,552,257</td>
</tr>
<tr>
<td>Grants falling due after more than one year</td>
<td>2,548,554</td>
<td>2,224,518</td>
</tr>
<tr>
<td></td>
<td>5,865,412</td>
<td>5,776,775</td>
</tr>
</tbody>
</table>

The foreign exchange loss arises on the restatement of grant creditors payable in a foreign currency. A number of these grants are payable after more than one year and the actual amount that will be paid will be dependent on the exchange rate at that time. The restatement of the foreign grant creditors resulted in an unrealised foreign exchange loss of £21,501 (2010: 43,682).

10. Creditors: amounts falling due within one year

<table>
<thead>
<tr>
<th></th>
<th>2011 Group £</th>
<th>2011 Charity £</th>
<th>2010 Group £</th>
<th>2010 Charity £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amounts due to subsidiary undertakings</td>
<td>-</td>
<td>6,125</td>
<td>-</td>
<td>19,430</td>
</tr>
<tr>
<td>Taxes and social security</td>
<td>34,473</td>
<td>34,063</td>
<td>34,155</td>
<td>34,155</td>
</tr>
<tr>
<td>Accruals and deferred income</td>
<td>183,478</td>
<td>179,837</td>
<td>259,135</td>
<td>255,415</td>
</tr>
<tr>
<td>Grants</td>
<td>217,951</td>
<td>219,825</td>
<td>293,290</td>
<td>309,000</td>
</tr>
<tr>
<td></td>
<td>3,534,809</td>
<td>3,536,683</td>
<td>3,845,547</td>
<td>3,861,257</td>
</tr>
</tbody>
</table>

11. Analysis of net assets between funds

<table>
<thead>
<tr>
<th></th>
<th>2011 Group Unrestricted funds £</th>
<th>2011 Group Restricted funds £</th>
<th>2011 Group Total funds £</th>
<th>2011 Group Total funds £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed assets</td>
<td>9,500,000</td>
<td>-</td>
<td>9,500,000</td>
<td>7,000,000</td>
</tr>
<tr>
<td>Net current assets</td>
<td>2,496,936</td>
<td>-</td>
<td>2,496,936</td>
<td>3,113,700</td>
</tr>
<tr>
<td>Creditors falling due after more than one year</td>
<td>(2,548,554)</td>
<td>-</td>
<td>(2,548,554)</td>
<td>(2,224,518)</td>
</tr>
<tr>
<td>Net assets at the end of the year</td>
<td>9,448,382</td>
<td>-</td>
<td>9,448,382</td>
<td>7,889,182</td>
</tr>
</tbody>
</table>
12. Statement of funds

At the start of the year | Incoming resources | Outgoing resources | Transfers | At the end of the year
--- | --- | --- | --- | ---

**Restricted funds**
- Leukaemia (see note below) | £827,199 | (827,199) | £ | £
- Prevention and Causes | £15,140 | (15,140) | £ | £
- Treatment | £49,494 | (49,494) | £ | £
- Welfare | £35,807 | (35,807) | £ | £

**Specific Projects**
- Dr Nick Goulden and Dr Chris Mitchell - UK ALL 2010 | £249,032 | £ | £ | £
- Professor Chris Boshoff, UCL - childhood cancer research programme | £50,000 | £ | (50,000) | £
- Leukaemia & Lymphoma Research - MRD study | £5,000 | £ | (5,000) | £
- Dr Persis Amrolia, UCL Institute of Child Health - immunotherapy project | £2,818 | £ | (2,818) | £

**Unrestricted funds**
- £1,234,490 | (927,640) | (306,850) | £ | £

**Total funds**
- £7,889,182 | £9,998,980 | (8,746,630) | £306,850 | £9,448,382

**Note**
The restricted funds comprise donations that were to be spent on specific causes and projects and these were all discharged during 2011.

The £827,199 received during the year relates to donations received specifically to be spent in the pursuit of our charitable objects in relation to Leukaemia only (as opposed to other forms of cancers or allied disorders). The remainder of the incoming resources that were restricted during the year relate to funds received towards grants that were previously paid out of unrestricted resources. Therefore, a total of £306,850 has been transferred from restricted back to unrestricted funds.

13. Staff costs

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and wages</td>
<td>£895,334</td>
<td>£811,055</td>
</tr>
<tr>
<td>National Insurance</td>
<td>£96,685</td>
<td>£86,241</td>
</tr>
<tr>
<td>Pension</td>
<td>£105,468</td>
<td>£96,830</td>
</tr>
</tbody>
</table>

**Total** | £1,097,487 | £994,126

During the year, one employee had emoluments between £90,000 and £100,000 and one employee had emoluments between £70,000 and £80,000 (2010: one employee had emoluments between £80,000 and £90,000 and one employee had emoluments between £60,000 and £70,000). Emoluments refer to gross salary and pension contributions made during the year.

The average weekly number of employees during the year, as calculated on a full time equivalent basis, was as follows:

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charitable Activities</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Generating Funds</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Governance, Operations and Administration</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

**Total** | 26 | 24

14. Related parties

Professor Denis Henshaw, a former Trustee (resigned 23rd February 2011), has previously been awarded grants totalling £32,883 in 2010 and £348,152 in 2009, payable to his institution University of Bristol. As at 31st December 2011, a total of £16,008 is owed to them and due to be paid in 2012.

Rodney Seddon, a former Trustee, is also a Trustee of the Venik Trust (charity number 1063185) and Paul O’Gorman Lifeline (charity number 1108060). The Venik Trust has donated £500,000 during the year and Paul O’Gorman Lifeline has received grants totalling £1,500,000. Rodney Seddon did not take part in discussions concerning the decision to make this grant.
## 15. Grants to third parties

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paul O’Gorman Lifeline.</strong>&lt;br&gt;To fund the treatment of children with leukaemia and other cancers from Eastern Europe.</td>
<td>£1,500,000</td>
<td>£750,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Tessa Holyoake, University of Glasgow.</strong>&lt;br&gt;Funding for senior lecturer in translational haemopoiesis (40% funding for 5 years).</td>
<td>323,603</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr K J Patel, MRC Laboratory of Molecular Biology.</strong>&lt;br&gt;Roles of aldehyde metabolism and DNA crosslink repair in fetal genome stability and leukaemogenesis.</td>
<td>300,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Kathy Pritchard-Jones, Institute of Child Health, London.</strong>&lt;br&gt;Molecular evolution of Wilms tumour.</td>
<td>283,597</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Morando Soffritti, Cesare Maltoni Cancer Research Centre.</strong>&lt;br&gt;Long-term carcinogenicity bio-assays to evaluate the potential biological effects of sinusoidal ELF EMF on Sprague Dawley rats.</td>
<td>263,852</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Faith Gibson, Great Ormond Street Hospital.</strong>&lt;br&gt;Evaluating HELP: an intervention for parents sharing information about leukaemia with their child.</td>
<td>251,743</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Irene Roberts, Imperial College London.</strong>&lt;br&gt;Global RNA profiles of trisomic, pre-leukaemic and leukaemic haemopoietic cells in Down syndrome.</td>
<td>205,373</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLIC Sargent.</strong>&lt;br&gt;Paul’s Fund: to provide financial assistance to the families of children being treated for leukaemia and other cancers.</td>
<td>200,000</td>
<td>200,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Darren Hargrave, Great Ormond Street Hospital.</strong>&lt;br&gt;Targeted therapies for childhood cancer: implementation of bio-marker driven early clinical trials.</td>
<td>198,011</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Owen Williams, Institute of Child Health, London.</strong>&lt;br&gt;The molecular basis for the impact of infectious exposure on the development of childhood leukaemia.</td>
<td>177,870</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Kate O’Neill, University of Oxford.</strong>&lt;br&gt;Investigating in utero exposures as possible origins of childhood cancers.</td>
<td>157,106</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Robert Newton, University of York.</strong>&lt;br&gt;Infection and cancer among children in sub-Saharan Africa.</td>
<td>102,129</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Charles Stiller, University of Oxford.</strong>&lt;br&gt;Why do increasing numbers of second cancers occur within five years after diagnosis of childhood cancer?</td>
<td>71,588</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Deborah Tweddle, University of Newcastle upon Tyne.</strong>&lt;br&gt;From human embryonic stem cells to sympathetic neurones: a model for understanding neuroblastoma pathogenesis.</td>
<td>68,255</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Michael Murphy, University of Oxford.</strong>&lt;br&gt;Resurrection of the database of the Oxford Survey of Childhood Cancers as a research resource and its use to investigate x-ray exposure.</td>
<td>63,952</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15. Grants to third parties (continued)

<table>
<thead>
<tr>
<th>Research into prevention and causes</th>
<th>Research into treatment</th>
<th>Welfare</th>
<th>Raising awareness &amp; education</th>
<th>Total 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>£</td>
<td>£</td>
<td>£</td>
<td>£</td>
<td>£</td>
</tr>
</tbody>
</table>
| **Shooting Star CHASE** (formerly CHASE Hospice Care).**
  To support the cost of services provided to children with leukaemia and other cancers. | 60,000 |
| Dr Michael Murphy, University of Oxford.  
  Record-based case-control study of childhood cancer and natural ionising radiation exposure. | 35,915 |
| Dr Lyndal Kearney, Institute of Cancer Research.  
  Extensions of existing grant ‘Defining the role of JAK2 mutations in the natural history and molecular pathogenesis of “excess risk” acute lymphoblastic leukaemia in children with Down syndrome’. | 31,430 |
| Dr Jude Fitzgibbon, Queen Mary University of London.  
  The genetics of familial leukaemia. | 17,682 |
| Dr George D Jones, University of Leicester.  
  AREF/UKEMS joint annual meeting 2011. | 10,000 |
| Leukaemia & Lymphoma Research.  
  Underspend on 2007 grant, reversed in 2011. | (477,592) |
| Professor Stephen Rappaport, University of California, Berkeley.  
  Underspend on 2009 grant, reversed in 2011. | (1,450) |
| Professor Tariq Enver, UCL Cancer Institute.  
  Infrastructure support to underpin research into the biology of normal and leukaemic stem and progenitor cells (three years from 2010). | 330,000 |
| Dr Pamela Kearns, University of Birmingham.  
  Infrastructure support to establish Children’s Oncology and Leukaemia Trials at the University of Birmingham’s CRUK Clinical Trials Unit. | 120,000 |
| Dr Michael Murphy and Dr Gerald Draper, Childhood Cancer Research Group, University of Oxford.  
  Project grant: Non-ocular cancers associated with retinoblastoma. | 168,039 |
| Marie Curie Cancer Care.  
  To fund a research associate in end of life care at Great Ormond Street Hospital (two years from 2011). | 85,733 |
| Dr Malcolm Taylor, University of Manchester.  
  Project grant: Preparation and testing of a recombinant BCG vaccine for childhood ALL expressing the TEL-AML1 (ETV6-RUNX1) oncoprotein. | 81,270 |
| Dr Michael Murphy, University of Oxford.  
  Extension of funding for post of Registry Assistant at the National Registry of Childhood Tumours. | 52,890 |
| Lifelites.  
  To support the provision of IT equipment to children’s hospices. | 48,000 |
### 15. Grants to third parties (continued)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Professor Patricia Buffler, University of California, Berkeley.</strong>&lt;br&gt;Childhood Leukemia International Consortium (CLIC) - to fund annual meetings in 2010, 2011 and 2012. **     37,736</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Denis Henshaw, University of Bristol.</strong>&lt;br&gt;Adjustment to programme grant awarded in 2008 (environmental causes of childhood leukaemia).     32,883</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Keech Hospice.</strong>&lt;br&gt;To support the cost of services provided to children with leukaemia and other cancers. Leukaemia CARE: To support the costs of running Care Line.     20,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Robert Mairs, University of Glasgow.</strong>&lt;br&gt;Underspend on 2006 grant, reversed in 2010.     (25,432)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Professor Mel Greaves, Institute of Cancer Research.</strong>&lt;br&gt;Underspend on 2006 grant, reversed in 2010.     (20,817)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Samuel Milham.</strong>&lt;br&gt;Underspend on 2005 grant, reversed in 2010.     (7,997)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Anand Chokkalingam, University of California, Berkeley.</strong>&lt;br&gt;Underspend on 2006 grant, reversed in 2010. **     (2,660)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Leeka Kheifets, University of California, Los Angeles.</strong>&lt;br&gt;Underspend on 2005 grant, reversed in 2010. **     (67)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Steve Selvin, University of California, Berkeley.</strong>&lt;br&gt;Underspend on 2006 grant, reversed in 2010. **     (58)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total grants to third parties**

|                      | 1,633,307 | 198,011 | 1,760,000 | 251,743 | 1,939,520 |

**Spend on campaigns, projects and programmes (excluding grants)**

|                      | 956,839 | 1,125,699 | 1,260,853 | 947,420 | 4,434,701 |

**Total resources expended on charitable activities**

|                      | 2,590,146 | 1,323,710 | 3,020,853 | 1,199,163 | 6,374,221 |

*Grant administered by Leukaemia and Lymphoma Research (registered charity no. 216032)

** Grant administered by the Regents of the University of California